Spironolactone Vaccine Interaction Profile: What Patients and Clinicians Need to Know

Does the Label Mention Vaccines?

The current Aldactone label's drug interaction section lists potassium-raising drugs and supplements, lithium, NSAIDs, digoxin, cholestyramine, aspirin, abiraterone and mitotane [1]. Vaccines are not among them [1]. The label's contraindications are hyperkalemia, Addison's disease and concomitant eplerenone [1]. The label gives no vaccine-specific dose adjustment or timing instruction [1]. The label's silence covers only what the label addresses; it is not a statement that every vaccine has been tested with spironolactone.

What the Label Does Warn About

Spironolactone increases sodium and water excretion while retaining potassium [1]. The label warns about hyperkalemia, hypotension and worsening renal function, electrolyte and metabolic abnormalities, and gynecomastia [1]. Hyperkalemia risk is increased by impaired renal function, potassium supplements, potassium-containing salt substitutes, and drugs that raise potassium such as ACE inhibitors and ARBs; the label also names NSAIDs, heparin and trimethoprim among drugs that can raise potassium [1]. The label says that if hyperkalemia occurs, the dose should be decreased or the drug discontinued and the hyperkalemia treated [1]. It also says excessive diuresis may cause symptomatic dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking ACE inhibitors or ARBs [1].

Is Spironolactone an Immunosuppressant?

Nothing in the Aldactone label describes spironolactone as immunosuppressive [1]. The labeled mechanism is competitive aldosterone antagonism at the aldosterone-dependent sodium-potassium exchange site in the distal renal tubule [1]. The label's list of voluntarily reported adverse reactions does include leukopenia (including agranulocytosis) and thrombocytopenia; the label says the frequency of these reports cannot be estimated [1]. The label does not link them to vaccine response.

Why This Comes Up in Acne Treatment

Spironolactone is used off-label for acne in women; acne is not an FDA-approved indication [1]. In the SAFA trial, 410 women were randomized to spironolactone 50 mg/day for 6 weeks then 100 mg/day to week 24, or placebo [2]. Its outcomes were acne-specific quality of life, investigator-rated success, participant-rated improvement and adverse effects [2].